Cytochrome P450 in Human Drug Metabolism: How Much Is Predictable?
Cytochrome P450 (CYP) mono-oxygenases represent one of the major enzyme systems that determine the organism’s capability of dealing with drugs and chemicals. Studies over the past 20 years have provided evidence that cytochromes P450 occur in many different forms (isoforms or isozymes) which differ in spectral, chemical, and immunological properties and have different substrate affinities. These isozymes also differ in their regulation and tissue distribution. Recombinant DNA studies indicate that between 50 and 200 structural genes may code for different cytochrome P450 isozymes in a single organism. Close to 30 human cytochrome P450 genes have now been characterized. The multiplicity of P450 isozymes explains in part the literally thousands of substrates known to be metabolized by this system (for review, see Nelson et al. 1993).
KeywordsPoor Metabolizers Human Cytochrome CYP2D6 Gene Cytochrome P450 Isozyme CYP2D6 Allele
Unable to display preview. Download preview PDF.
- DeMorais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for thepolymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269: 15422–15422Google Scholar
- Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI (1994) Evidence that CYPC19 is the major s-mephenytoin 4’hydroxylase in humans. Biochemistry (in press)Google Scholar
- Kalow W (1992) Pharmacogenetics of drug metabolism international encyclopedia of pharmacology and therapeutics (executive editor AC Sartorelli). Pergamon, LondonGoogle Scholar
- Kalow W, Goedde HW, Agarwal DP (1986) Ethnic differences in reactions to drugs and xenobiotics. Liss, New YorkGoogle Scholar
- Kronbach T, Fischer V, Meyer UA (1988) Cyclosporine metabolism in human liver: identification of a cytochrome P450 of the P450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43: 630–635PubMedCrossRefGoogle Scholar
- Meyer UA (1994) Pharmacogenetics: the slow, the rapid, and the ultrarapid. Proc Natl Acad Sci USA 91 (in press)Google Scholar
- Meyer UA, Zanger UM, Grant D, Blum M (1990) Genetic polymorphisms of drug metabolism. In: Testa B (ed) Advances in drug research, vol 19. Academic, London, pp 307–23Google Scholar
- Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O, Okuda K, Nebert DW (1993) the P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 12: 1–51Google Scholar
- Wilkinson GR, Guengerich FP, Branch RA (1992) Genetic polymorphism of S-mephenytoin hydroxylation. In: Kalow W (ed) Pharmacogenetics of drug metabolism, vol 2. Pergamon, New York, 657–685Google Scholar